Table 2 Univariate and multivariate analyses with respect to relapse-free survival in breast cancer subtypes

All breast cancer (n = 237)

 Age (≤ 56)

0.877–2.565

0.828–4.847

 Menopause (−)

0.709–2.074

0.310–1.802

 Tumor size (> 2)

0.738–4.830

0.640–4.436

 Lymph node (+)

0.904–3.620

0.950–3.880

 Nuclear grade (3)

0.427–1.713

0.642–3.064

 Ki67 (> 14)

0.325–0.945

0.300–0.991

 Pathological response (non-pCR)

1.143–3.891

1.005–3.746

Luminal (n = 93)

 Age (≤ 56)

0.537–2.871

0.988–20.715

 Menopause (−)

0.367–1.974

0.072–1.290

 Tumor size (> 2)

0.607–13.00

0.650–16.093

 Lymph node (+)

0.935–19.94

1.336–31.230

 Nuclear grade (3)

0.365–2.799

0.640–8.278

 Ki67 (> 14)

0.256–1.360

0.119–0.906

 Pathological response (non-pCR)

0.487–3.281

0.513–4.387

HER2-enriched (n = 43)

 Age (≤ 56)

0.559–8.614

0.050–9.029

 Menopause (−)

0.463–7.126

0.451–175.683

 Tumor size (> 2)

0.195–19.750

0.024–6.713

 Lymph node (+)

0.447–12.523

0.292–15.232

 Nuclear grade (3)

0.022–2.245

0.007–1.387

 Ki67 (> 14)

0.160–2.460

0.140–6.349

 Pathological response (non-pCR)

0.412–6.289

0.569–55.264

TNBC (n = 80)

 Age (≤ 56)

0.611–3.697

0.542–10.890

 Menopause (−)

0.515–3.195

0.136–2.660

 Tumor size (> 2)

0.333–7.263

0.160–4.296

 Lymph node (+)

0.411–3.282

0.214–2.083

 Nuclear grade (3)

0.314–2.999

0.679–11.523

 Ki67 (> 14)

0.202–1.250

0.150–1.518

 Pathological response (non-pCR)

1.557–14.857

1.612–19.386